Business · 07/06/2024Updated: 10/17/2026 · 1 min read
FDA Announces Public Meeting of Oncologic Drugs Advisory Committee for IMFINZI (durvalumab) Injection
The FDA is hosting a public meeting of the Oncologic Drugs Advisory Committee to provide advice on the Supplemental Biologics License Application 761069/S-043 for IMFINZI (durvalumab) Injection, and is seeking public comments on the matter.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →